Blueberries Medi Stock Price, News & Analysis

Blueberries Medical Corp. (OTC: BBRRF) is a Latin American licensed producer of medicinal cannabis and cannabis-derived products. The company’s primary operations are located in the Bogotá Savannah region of central Colombia, a geography it describes as advantageous for cultivating naturally grown, premium-quality cannabis. Through its Colombian subsidiary, Blueberries S.A.S., the business focuses on medicinal cannabis and medicinal-grade cannabis extracts.

According to company disclosures, Blueberries is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of CBD- and THC-based medical cannabis. It operates in the medicinal and botanical manufacturing space within the broader manufacturing sector, with an emphasis on cannabis derivatives and standardized medicinal-grade cannabis oil extracts and related products.

Business focus and operations

Blueberries describes itself as a producer of naturally grown premium-quality cannabis and cannabis derivatives. Its activities include producing CBD and THC derivatives, such as standard oil products and other cannabis extracts, and offering extraction-related services. Company materials state that CBD derivatives (standard oil) have represented a significant share of revenue, alongside extraction services and sales of clones derived from CBD seeds.

The company has reported a strategic shift over time from a primary focus on cultivation toward extraction services and isolated products. It has highlighted a niche in the export market for isolated products to Latin American countries, and has referenced the development and sale of CBD isolate, THC and CBD isolates, and other derivatives. Blueberries has also indicated that it launched tolling services, processing flower and biomass from small and mid-size licensed producers, and that extraction services have become a core part of its commercial model.

Licensing and regulatory context

Blueberries’ disclosures emphasize that it operates under Colombia’s medical cannabis regulatory framework. The company notes that it is licensed for psychoactive and non-psychoactive cannabis activities and has received psychoactive and non-psychoactive cannabis flower export licenses from the Colombian Ministry of Justice. It has also referenced Colombian regulatory developments, including Decree 811 and related resolutions that address exportation of cannabis derivatives and dry flower, use of non-psychoactive cannabis in food and beverages, and extended license terms.

Blueberries participates in the Colombian cannabis industry through membership in the Asociación Colombiana de Industrias de Cannabis (Colombian Association of Cannabis Industries), according to its own statements. The company has indicated that it monitors regulatory changes closely to prepare for opportunities in exports of dry flower and derivatives, distribution through pharmacies, and supply of ingredients for food, beverage, cosmetic, and veterinary applications.

International markets and distribution

Company communications describe Blueberries as focused on Latin American and international markets. It has reported commercial activity in multiple countries, including exports of CBD and THC isolates and derivatives to markets such as Argentina, Peru, and Australia, and has referenced customers in Brazil and Chile. The company has also indicated that it has developed or pursued arrangements aimed at accessing markets in Europe, the United States, and additional Latin American jurisdictions.

Blueberries has highlighted that its combination of scientific expertise, agricultural conditions in Colombia, and distribution arrangements has, in its view, positioned the company to become an international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products. It has also reported entering the Argentine pharmaceutical market through sales of cannabidiol for pharmaceutical purposes.

Partnerships and collaboration model

In its public updates, Blueberries has described a business approach that includes alliances and joint ventures with other cannabis and pharmaceutical sector participants. Examples mentioned by the company include:

• Agreements with large Colombian cultivators to secure GACP-certified CBD and THC biomass and flowers at lower unit costs than historical in-house cultivation.
• A joint venture agreement with a Colombian subsidiary of Allied Corp to produce THC and CBD derivatives, combining cultivation and extraction capabilities.
• Arrangements with partners such as Econnabis S.A.S. and BG Labs to outsource cultivation and share revenues from CBD broad spectrum products.
• Collaboration with Nutripharma, a pharmaceutical laboratory, around pharmaceutical active ingredients and finished products.

Blueberries has indicated that these partnerships are intended to allow it to focus resources on extraction, purification, and transformation processes, while leveraging third-party cultivation capacity. The company has also referenced work with cosmetic and pharmaceutical laboratories in Latin America for the supply of cannabinoid ingredients.

Product and service profile

Based on its own disclosures, Blueberries’ activities span several product and service categories within medicinal cannabis manufacturing:

• Cannabis derivatives and extracts: CBD and THC derivatives, including standard oil products and other medicinal-grade cannabis oil extracts.
• Isolated products: CBD isolate and other isolates such as CBG and CBN for use in cosmetic, pharmaceutical, and other applications.
• Extraction services: Processing flower and biomass from third-party licensed producers, including tolling services.
• Specialty ingredients: Development of non-psychoactive, high value-added ingredients for food and beverages and other uses, including a CBD water-soluble powder described by the company as suitable for water-based products.
• Clones and plant material: Sales of cloned cuttings and clones derived from CBD seeds, particularly in earlier stages of its operations.

These activities align with the company’s classification in medicinal and botanical manufacturing, with a focus on cannabis-derived ingredients and intermediates for downstream customers.

Corporate structure and financing

Blueberries Medical Corp. is described as the Canadian parent of Blueberries S.A.S., which operates in Colombia. The company’s shares trade on the Canadian Securities Exchange under the symbol BBM and on the OTC market under the symbol BBRRF, and it has also referenced a Frankfurt listing under the symbol 1OA. The business has relied on non-brokered private placements and convertible debentures as key financing tools.

Multiple news releases detail private placements led by Terraflos Inc., a company with operations throughout Latin America that is founded and controlled by an individual who also serves as Blueberries’ chairman and chief executive officer. These financings have involved the sale of common shares to Terraflos and other participants, with proceeds allocated to repay debt, support operations, fund working capital, and expand manufacturing and commercial capabilities.

Strategic themes

Across its public communications, Blueberries emphasizes several recurring strategic themes:

• Shift toward extraction and derivatives: Pivoting from a cultivation-centric model to focus on extraction services, isolates, and derivatives.
• Cost optimization: Reducing operating expenses, general and administrative costs, and infrastructure-related spending, including changes in facility leases and outsourcing cultivation.
• Regulatory-driven opportunities: Aligning product development and export plans with evolving Colombian and international regulations on medical cannabis and cannabis derivatives.
• Latin American focus with global reach: Building a base in Colombia and Latin America while targeting exports to markets such as Australia and exploring opportunities in other regions.

These elements define the company’s stated approach within the medicinal and botanical manufacturing segment of the cannabis industry.

Position within the cannabis industry

Blueberries describes itself as a Latin American licensed cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts. It operates as part of the medical cannabis supply chain, supplying derivatives, isolates, and extraction services to other industry participants and to customers in pharmaceutical, cosmetic, and related sectors. The company’s narrative highlights its Colombian operational base, regulatory licenses, and partnerships as key components of its role in the regional cannabis ecosystem.